Pharmaceutical

RegenxBio touts positive data for rare disease drug RGX...

RGX-121 has been evaluated in the Phase I/II/III CAMPSIITE study as a one-time g...

Ocaliva approval in Europe withdrawn following data re-...

Advanz Pharma, Ocaliva’s manufacturer, said thousands of patients will no longer...

ESC 2024: CATHEDRAL-HF trial results have the potential...

A large proportion of chronic heart failure (HF) patients are taking suboptimal ...

Diabetes duration has minimal impact on SGLT2 inhibitor...

A meta-analysis has demonstrated consistent efficacy in heart failure outcomes w...

ESC 2024: Study highlights potential for Novartis to di...

There is a strong opportunity in the heart failure (HF) space for new agents tha...

Generalized Pustular Psoriasis (GPP) drugs in developme...

GlobalData tracks 6 drugs in development for Generalized Pustular Psoriasis (GPP...

Frontotemporal Dementia (FTD) drugs in development, 2024

GlobalData tracks 119 drugs in development for Frontotemporal Dementia (FTD) by ...

Aromatic l-Amino Acid Decarboxylase (AADC) Deficiency d...

GlobalData tracks 6 drugs in development for Aromatic l-Amino Acid Decarboxylase...

ESC 2024: Latest FLOW trial analysis highlights how Oze...

If approved, Novo Nordisk's Ozempic will become the first GLP-1 therapy option f...

J&J targets generalised myasthenia gravis landscape wit...

J&J’s BLA was supported by data from the Phase III VIVACITY study, demonstrating...

ESC 2024: Amvuttra data signals positive prospects in c...

Alnylam announced positive final results from the Helios-B trial for patients wi...

ESC 2024: Obesity drugs emerge as attractive tool for h...

Experts discuss the relationship between obesity and heart failure while referen...

Acute On Chronic Liver Failure (ACLF) drugs in developm...

GlobalData tracks 15 drugs in development for Acute On Chronic Liver Failure (AC...

Non-infectious Uveitis drugs in development, 2024

GlobalData tracks 19 drugs in development for Non-infectious Uveitis by 20 compa...

Atypical Teratoid Rhabdoid Tumor drugs in development, ...

GlobalData tracks 18 drugs in development for Atypical Teratoid Rhabdoid Tumor b...

EC upgrades approval for J&J’s Rybrevant/chemotherapy c...

Rybrevant has been granted a Type II approval extension to treat NSCLC with EGFR...